ProShare Advisors LLC reduced its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 19.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 13,760 shares of the company's stock after selling 3,250 shares during the period. ProShare Advisors LLC's holdings in Turning Point Therapeutics were worth $370,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtus ETF Advisers LLC raised its holdings in shares of Turning Point Therapeutics by 51.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,131 shares of the company's stock valued at $197,000 after acquiring an additional 1,396 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Turning Point Therapeutics by 39.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 5,106 shares of the company's stock valued at $244,000 after purchasing an additional 1,443 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Turning Point Therapeutics by 21.9% in the fourth quarter. Teacher Retirement System of Texas now owns 8,037 shares of the company's stock valued at $383,000 after purchasing an additional 1,446 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Turning Point Therapeutics in the first quarter valued at about $243,000. Finally, CNA Financial Corp grew its stake in Turning Point Therapeutics by 50.8% in the fourth quarter. CNA Financial Corp now owns 9,083 shares of the company's stock valued at $433,000 after purchasing an additional 3,060 shares during the last quarter. 90.33% of the stock is currently owned by institutional investors.
Get Turning Point Therapeutics alerts:Insider Buying and Selling at Turning Point Therapeutics
In other Turning Point Therapeutics news, CFO Paolo Tombesi sold 1,183 shares of the business's stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total value of $88,654.02. Following the completion of the transaction, the chief financial officer now directly owns 28,700 shares of the company's stock, valued at $2,150,778. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.60% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
TPTX has been the topic of several analyst reports. Cowen lowered Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, June 6th. Wells Fargo & Company lowered Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 target price on the stock. in a research note on Friday, June 3rd. The Goldman Sachs Group dropped their price target on Turning Point Therapeutics from $143.00 to $116.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th. Wedbush lowered Turning Point Therapeutics from an "outperform" rating to a "neutral" rating and boosted their price target for the stock from $61.00 to $76.00 in a research note on Friday, June 3rd. Finally, Cowen lowered Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, June 6th. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $78.22.Turning Point Therapeutics Stock Up 0.7 %
Shares of NASDAQ TPTX opened at $76.01 on Monday. The business's 50 day moving average price is $75.30 and its 200 day moving average price is $50.28. The firm has a market cap of $3.81 billion, a P/E ratio of -11.02 and a beta of -0.18. Turning Point Therapeutics, Inc. has a 52 week low of $23.77 and a 52 week high of $82.20.
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last issued its earnings results on Monday, August 8th. The company reported ($2.48) EPS for the quarter, missing analysts' consensus estimates of ($1.78) by ($0.70). The company had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. The firm's revenue was down 97.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.14) EPS. As a group, research analysts expect that Turning Point Therapeutics, Inc. will post -7.69 earnings per share for the current year.
Turning Point Therapeutics Company Profile
(Get Rating)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Recommended Stories
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding TPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating).
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.